A composition for the prevention or treatment of fibrosis, comprising a CDK17 expression or activity inhibitor

Composition for preventing and treating fibrosis through inhibition of CDK17 expression and activity

This technology relates to a composition for preventing and treating fibrosis, comprising as an active ingredient a substance that inhibits the expression or activity of CDK17 (cyclin-dependent kinase 17).

Fibrosis causes organ damage and fatal diseases due to the excessive accumulation of extracellular matrix, but there have been insufficient therapeutic targets that can effectively inhibit fibrosis in various organs.

This technology confirms that CDK17 inhibition significantly reduces collagen production and cell activity in liver, kidney, and lung fibrosis cell models, thereby offering excellent therapeutic effects broadly applicable to fibrosis in various organs.

‍

‍

Key Features:

• A pharmaceutical composition comprising a CDK17 expression or activity inhibitor as an active ingredient
• Reduced collagen production and cell activity in liver fibrosis models, including hepatic stellate cells
• Inhibition of fibrotic response in TGF-β-induced kidney and lung fibrosis models
• An approach to preventing and treating fibrosis by targeting excessive extracellular matrix accumulation